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The contribution of the different waves and sites
of developmental hematopoiesis to fetal and adult
blood production remains unclear. Here, we identify
lymphatic vessel endothelial hyaluronan receptor-1
(LYVE1) as a marker of yolk sac (YS) endothelium
and definitive hematopoietic stem and progenitor
cells (HSPCs). Endothelium in mid-gestation YS
and vitelline vessels, but not the dorsal aorta and
placenta,were labeledbyLyve1-Cre.MostYSHSPCs
and erythro-myeloid progenitors were Lyve1-Cre
lineage traced, but primitive erythroid cells were
not, suggesting that they represent distinct lineages.
Fetal liver (FL) and adult HSPCs showed 35%–40%
Lyve1-Cre marking. Analysis of circulation-deficient
Ncx1/ concepti identified the YS as a major source
of Lyve1-Cre labeled HSPCs. FL proerythroblast
marking was extensive at embryonic day (E) 11.5–
13.5, but decreased to hematopoietic stem cell
(HSC) levels by E16.5, suggesting that HSCs from
multiple sources became responsible for erythropoi-
esis. Lyve1-Cre thus marks the divergence between
YS primitive and definitive hematopoiesis and pro-
vides a tool for targeting YS definitive hematopoiesis
and FL colonization.INTRODUCTION
Developmental hematopoiesis is composed of temporally
orchestrated programs that generate both the differentiated
blood cells to support embryonic growth and the undifferenti-
ated hematopoietic stem cells (HSCs) to sustain post-natal he-
matopoiesis. This challenge is met by segregating hematopoie-
sis into multiple waves that occur in different anatomical
locations. The earliest (‘‘primitive’’) hematopoietic wave starts2286 Cell Reports 17, 2286–2298, November 22, 2016 ª 2016 The A
This is an open access article under the CC BY-NC-ND license (http://in the extra-embryonic yolk sac (YS) at embryonic day (E) 7.5
and gives rise to erythroid cells that fulfill the immediate meta-
bolic needs of the embryo (EM) (Moore and Metcalf, 1970).
They are characterized by the expression of embryonic b globin
(betaH1 in mice) (Haar and Ackerman, 1971). At E8.5–9.5, the YS
also generates an intermediate (‘‘transient-definitive’’) wave of
erythro-myeloid progenitors (EMPs) (McGrath et al., 2015; Mik-
kola and Orkin, 2006; Palis et al., 1999) that produce red cells ex-
pressing ‘‘definitive’’ adult type b globins (beta-major in mice)
(McGrath et al., 2003). However, YS EMPs lack self-renewal
ability and lymphoid potential, the hallmarks of HSCs. It has
been proposed that EMPs initiate fetal liver (FL) definitive hema-
topoiesis and play roles in supporting embryonic survival (Chen
et al., 2011), inflammatory signaling during HSC emergence (Es-
pı´n-Palazo´n et al., 2014), and adult tissue-resident macrophage
development (Gomez Perdiguero et al., 2015). However, the
duration and significance of this intermediate hematopoietic
wave are not fully understood.
The final (‘‘definitive’’) wave generates self-renewing, multipo-
tent HSCs that sustain lifelong production of all blood cell
types. Transplantable HSCs are first identified at E10.5–11.5
in the intra-embryonic para-aortic splanchnopleural/aorta-
gonad-mesonephros region (pSP/AGM) and the vitelline and
umbilical vessels that connect the pSP/AGM to extra-embry-
onic tissues (Medvinsky and Dzierzak, 1996; M€uller et al.,
1994). Several studies suggest that the YS and the placenta
(PL) can also generate multipotent hematopoietic stem and pro-
genitor cells (HSPCs) de novo (Inlay et al., 2014; Rhodes et al.,
2008; Samokhvalov et al., 2007; Weissman et al., 1977, 1978;
Zeigler et al., 2006). Observations from direct transplantation
of pre-circulation YS into congenic embryos and inducible
Runx1 lineage-tracing studies supported the hypothesis that
YS contributes to adult hematopoiesis (Samokhvalov et al.,
2007; Weissman et al., 1977, 1978). Furthermore, in vitro exper-
iments with placental tissues isolated before or without the
onset of blood circulation demonstrated multi-lineage hemato-
poietic potential (Rhodes et al., 2008; Zeigler et al., 2006). How-
ever, the degree to which each organ contributes to the post-
natal HSC pool is unknown.uthors.
creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. LYVE1 Protein Is Expressed in Yolk Sac Endothelium and Hematopoietic Stem and Progenitor Cells
(A) LYVE1 protein is detected by IF in E10.5 YS, vitelline vessels (VVs), and the cardinal vein (CV), but is absent from the PL, umbilical vessels (UVs), and DA.
Representative images from three independent experiments. Scale bar, 100 mm.
(B) IF staining shows co-localization of LYVE1 in E9.5 YS CD31+ endothelium. Representative image from three independent experiments. Scale bar, 100 mm.
(C) FACS analysis of CD31+CD41Ter119 endothelium in YS, PL, and caudal half of the EM of one representative E9.5 conceptus. Corresponding histograms
of LYVE1+ endothelial cells show robust LYVE1 expression in YS endothelium only. Data from n = 11 from three independent experiments are represented as
mean ± SD; ***P% 0.001.
(legend continued on next page)
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Lineage tracing and time-lapsed imaging of HSPC emergence
in vitro and in vivo evidenced that definitive HSPCs arise from
specialized endothelial cells, named hemogenic endothelium
(Bertrand et al., 2010; Boisset et al., 2010; Chen et al., 2009;
Eilken et al., 2009; Lancrin et al., 2009; Zovein et al., 2008).
Hemogenic competence in the endothelium is established by
the stem cell leukemia gene/T cell acute leukemia gene 1 (Scl/
Tal1), which activates a broad transcriptional network of hemato-
poietic regulators and prevents misspecification of the endothe-
lium to cardiac fate (Van Handel et al., 2012). SCL activates
RUNX1 and other transcription factors that enable HSPC emer-
gence from hemogenic endothelium (Org et al., 2015). SCL is
also essential for the generation of primitive erythroid cells and
controls the terminal maturation of erythroid cells at all stages
of ontogeny (Mikkola et al., 2003a; Schlaeger et al., 2005; Shiv-
dasani et al., 1995). The identity of the precursors for the primi-
tive erythroid cells and the timing when they diverge from the
definitive hematopoietic lineages are not known. The presump-
tion that primitive and definitive hematopoietic waves represent
distinct lineages that arise from their own precursors (‘‘lineage
switch’’ model) has been challenged by studies that show
sequential expression of both the primitive and definitive
globins (‘‘maturational switch’’ model) during erythroid matura-
tion (Kingsley et al., 2006; McGrath et al., 2011; Palis, 2008;
Qiu et al., 2008).
Although the fundamentals of the developmental hematopoi-
etic hierarchy are gradually being revealed, the contributions of
each wave and hemogenic tissue to fetal and post-natal hema-
topoiesis remain poorly defined because of the lack of wave-
and tissue-specific tools that would enable prospective isolation
and tracking of the progeny of the temporally and spatially over-
lapping blood precursors. Most surface antigens expressed in
the hemogenic endothelium or emerging HSPCs—e.g., Flk1,
CD31, VE-Cadherin, Tie2, CD41, ckit, and Sca1—are develop-
mentally regulated but not specific to any individual wave or
anatomical site (McKinney-Freeman et al., 2009; Mikkola and
Orkin, 2006). The use of inducible lineage-tracing studies using
regulatory elements of hematopoietic transcription factors
(e.g., Runx1) is complicated by the fact that the expression of
such factors is not restricted to a particular hemogenic tissue
(Samokhvalov et al., 2007). Thus, there are no robust methods
to separate or genetically target in vivo individual hematopoietic
waves or hemogenic tissues.(D) LYVE1 protein is not discernible by IF in Ter119+ primitive erythroid cells in E
Scale bar, 50 mm.
(E) Representative FACS plots indicate that Ter119+ primitive erythroid cells (pRB
(F) IF staining of E9.5 YS shows co-expression of LYVE1 protein with HSPC mark
Scale bar, 50 mm.
(G) Representative FACS plots show LYVE1 expression in CD41midcKit+Ter119
(H) Representative FACS plots of E13.5 FL document minimal LYVE1 expression
(I) LYVE1 expression is prominent in mid-gestation YS HSPCs and EMPs. Data fro
experiments for YS HSPC; n = 8, three independent experiments for YS EMP;
mean ± SD.
(J) Representative FACS plots of hemogenic tissues inNcx1/ E9.5 concepti dem
the YS.
(K) Significantly higher HSPC fraction in the YS than in the PL or EM expresses LY
for Ncx1/ from five independent experiments is represented as mean ± SD. p
See also Figure S1 and Table S1.
2288 Cell Reports 17, 2286–2298, November 22, 2016Here, we identify the lymphatic vessel endothelial hyaluronan
receptor 1 (LYVE1) as amarker that is differentially and highly ex-
pressed in YS endothelium during HSPC development. Lineage
tracing by reporter gene expression and conditional deletion of
the hematopoietic regulators Scl andRunx1 by Lyve1-Cre distin-
guished YS endothelium, EMPs, and definitive HSPCs from the
primitive erythroid lineage. Our data suggest that Lyve1-Cre-
labeled cells primarily originate from the YS and/or vitelline ves-
sels and contribute to 35%–40% of fetal and adult HSC com-
partments. At E11.5, the FL pro-erythroblast pool is dominated
by LYVE1-lineage cells, whereas by late gestation, the level of
marking is similar to the HSC compartment, implying a temporal
switch in the composition of precursors responsible for FL eryth-
ropoiesis. Lyve1-Cre thus provides a unique tool to investigate
the contribution of YS hemogenic endothelium to fetal and adult
hematopoiesis and the factors that regulate the fate of these
cells.
RESULTS
LYVE1 Protein Is Expressed in YS Endothelium and
Definitive Hematopoietic Cells
To define the precursors and respective contributions of the
different waves to fetal and adult hematopoiesis, we sought for
cell surface markers expressed in hemogenic endothelium that
are tissue or wave specific. From a list of genes encoding surface
proteins highly expressed in YS endothelium (Van Handel et al.,
2012), Lyve1 emerged as a promising candidate. Initially re-
ported as a marker for lymphatic vessels, LYVE1 expression
was later documented also in mid-gestation YS vasculature,
FL sinusoids, intersomitic vessels, and the cardinal vein, while
being minimal in the dorsal aorta (DA) (Banerji et al., 1999; Gor-
don et al., 2008).
Because LYVE1 expression has not been assessed in the
context of developmental hematopoiesis, LYVE1 protein expres-
sion was surveyed in hemogenic organs by immunostaining and
flow cytometry (FACS). Immunofluorescence (IF) at E10.5
demonstrated robust LYVE1 protein expression in YS and vitel-
line vasculature, whereas no signal was observed in the PL,
umbilical vessels, and DA (Figure 1A). As reported previously,
LYVE1 was also expressed in the cardinal vein at E10.5. At
E9.5, LYVE1 protein expression in CD31+ endothelial cells was
ubiquitous in the YS, but minimal in the EM and PL (Figures 1B10.5 YS. Representative image from two independent experiments is shown.
Cs) do not express LYVE1 in E9.5 YS or E11.0 peripheral blood (PB).
er CD41. Representative image from three independent experiments is shown.
HSPCs and its subset, CD16/32+ EMPs in E9.25 YS.
in LinSca1+cKit+ CD150+ HSC compartment.
m n = 8, three independent experiments for YS pRBC; n = 28, 10 independent
and n = 6, two independent experiments for FL HSC subset are shown as
onstrate the enrichment of LYVE1-expressing CD41midcKit+Ter119HSPCs in
VE1 protein in Ncx1/ concepti. Quantification of n = 23 for control and n = 11
values refer to the difference between LYVE1+ fractions; ****P% 0.0001.
Figure 2. Lyve1-Cre Labels Yolk Sac Endothelium and Vitelline Vessels
(A) Schematic of mouse model for tracing Lyve1-Cre lineage cells using the RosamT/mG reporter line.
(B) Brightfield and whole mount fluorescence microscopy images of Lyve1-Cre;mTmG E8.5 concepti show the replacement of Tomato (red) by GFP (green)
expression in the YS. Representative image from n = 8 concepti from two independent experiments. Scale bar, 500 mm.
(legend continued on next page)
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and 1C). Scant LYVE1 protein was discernible in PL vasculature
during HSPC emergence (E11.5) and expansion/maturation
(E13.5); however, some LYVE1 protein could be detected at
late gestation (E16.5) when the PL HSC pool has already dimin-
ished (Gekas et al., 2005) (Figure S1A). At E13.5, LYVE1 expres-
sion was also abundant in FL sinusoids and the azygous vein—
tissues incapable of de novo HSPC generation—but not the
aorta (Figure S1B).
Analysis of the early concepti revealed LYVE1 expression in
Tie2+CD31+ angioblasts already by E7.5 (Figure S1C). At E8.5,
LYVE1 was present in YS Tie2+CD31+ angioblasts, but excluded
from Ter119+ primitive erythroid cells (Figure S1C), the embryo,
and allantois (data not shown). These data identify the YS and
the vitelline vessels as the primary sites harboring LYVE1-
expressing endothelium during HSPC emergence. Moreover,
these data imply that LYVE1 protein is already expressed in
the YS at the time when primitive hematopoiesis begins and
the endothelium that gives rise to YS definitive lineages is
specified.
We next assessed the expression of LYVE1 protein in YS
hematopoietic cells. IF and FACS analyses showed that
Ter119+ primitive erythroid cells were devoid of LYVE1 expres-
sion (Figures 1D, 1E, and 1I). In contrast, LYVE1 expression
was observed in 47.0% ± 19.1% SD of E9.25–9.5 YS
CD41midcKit+Ter119 HSPC population (Figures 1F, 1G, and
1I), which consists predominantly of EMPs (Ferkowicz et al.,
2003; Mikkola et al., 2003b). Co-staining for the EMP marker
CD16/32 (McGrath et al., 2015) suggested that most LYVE1+
HSPCs in E9.25 YS are EMPs (Figure 1G). In contrast to YS
HSPCs and EMPs, the E13.5 FL LSK (LinSca1+cKit+) CD150+
HSC subset showed minimal LYVE1 expression (Figures 1H
and 1I).
To assess the origin of LYVE1+ HSPCs, LYVE1 expression
was examined in concepti that were devoid of blood circulation
due to a defective sodium calcium exchanger (Ncx1) required
for cardiac activity (Koushik et al., 2001). FACS analysis of
Ncx1/ tissues showed that LYVE1 expression was robust in
CD41midcKit+ HSPCs in the YS, but minimal in the PL or EM (Fig-
ures 1J and 1K). Comparable results were observed with CD16/
32+CD41midcKit+ EMPs (Figure S1D). These data suggest that
the YS is the primary source of LYVE1+-expressing HSPCs,
including EMPs, in mid-gestation concepti.
Lyve1-Cre Labels YS Endothelium and Vitelline Vessels
To define the contribution of LYVE1+ candidate hemogenic
endothelial cells to fetal and adult hematopoiesis, lineage tracing(C) Brightfield and whole mount fluorescence microscopy images of YS, EM, and
the vitelline vessels (VV; green arrow). (ii) shows intact Tomato activity in PL and um
cells (green arrowheads) are found in PL vasculature (ii), heart (H) and limb bud (L
vasculature (iv). Representative image of n = 18 embryos from three independen
(D) At E10.5, GFP labeling is widespread in YS and VV CD31+ endothelium, but
Scale bar, 250 mm.
(E) Representative FACS plots of GFP labeling of VE-Cad+CD31+ endothelial cel
(F) Bar graphs of endothelial cells show robust Lyve1-Cre lineage tracing in YS at
gonad-mesonephros region at E10.5 and E11.5. Data are from pools of embryos fr
are represented as mean ± SD.
See also Table S1.
2290 Cell Reports 17, 2286–2298, November 22, 2016was performed by breeding Lyve1-eGFP-hCre knockin mice
(Pham et al., 2010) (referred as ‘‘Lyve1-Cre’’ hereafter) with re-
porter mouse lines. As originally reported, endogenous eGFP
signal from the Lyve1-Cre line was weak and did not interfere
with the signal from the reporter GFP. We first used RosamT/mG
fluorescent reporter mice (Figure 2A), in which all cells of the
conceptus initially express tdTomato. Upon activation of Cre re-
combinase, the floxedmembrane-targeted tdTomato cassette is
excised, allowing the expression of the downstreammembrane-
targeted EGFP in Cre-expressing cells and their progeny (Mu-
zumdar et al., 2007). Maternal blood cells in the PL could be
separated from the cells of the conceptus because they were
devoid of any fluorescence.
Analysis of Lyve1-Cre;RosamT/mG concepti by fluorescence
microscopy demonstrated Lyve1-Cre labeling already in E8.5
YS (Figure 2B). By E10.5, marking was apparent in YS and vitel-
line vessels as well as the FL (Figures 2Ci, 2Ciii, and 2Civ), but
absent from umbilical and placental large vessels (Figure 2Cii).
In contrast to the robust labeling of CD31+ YS and vitelline ves-
sels, the dorsal aorta showed minimal Lyve1-Cre labeling (Fig-
ures 2C and 2D).
FACS analysis of hemogenic tissues from Lyve1-Cre;
RosamT/mG concepti at E9.5–E11.5 further documented that
VE-Cad+CD31+ endothelial cells were GFP labeled abundantly
in the YS but minimally in the PL and EM (the latter includes
the caudal half at E9.5 and the aorta-gonad-mesonephros region
at later ages) (Figures 2E and 2F). These data raised the hypoth-
esis that Lyve1-Cre labels YS hemogenic endothelium.
Lyve1-Cre Lineage Traces YS Definitive HSPCs but
Bypasses the Primitive Erythroid Lineage
We next interrogated the contribution of LYVE1 lineage cells
to the different hematopoietic compartments. Lyve1-Cre was
crossed with a R26-stop-YFP strain, where deletion of the
transcriptional stop preceding the YFP sequence in the
Rosa26 locus leads to marking of all progenies with YFP (Fig-
ure 3A) (Friedrich and Soriano, 1991).
FACS analysis of E8.5 Lyve1-Cre;YFP YS showed labeling in
one-third of angioblasts, whereas none of the Ter119+ primitive
erythroid cells were marked (Figure 3B). Likewise, no labeling
was observed in Ter119+ cells in E9.0 Lyve1-Cre;YFP YS,
although 90% of erythroid cells were labeled when the YFP re-
porter strain was crossed with Tie2/Tek-Cre mouse, in which
Cre is activated in hemato-vascular precursors after gastrulation
(Figure 3C) (Kisanuki et al., 2001). 100% labeling was observed
with the germ-cell-specific Vasa-Cre mouse, in which Cre isPL at E10.5. (i) shows GFP expression in the fetal liver (FL; dashed outline) and
bilical vessels (UV; red arrow) and in the dorsal aorta (DA). GFP+ hematopoietic
B; dashed outline) (iii), and YS (iv). GFP expression is prominent throughout YS
t experiments. Scale bar, 500 mm.
minimal in the DA. Representative image from two independent experiments.
ls in E9.5 YS, PL, and caudal half of the EM.
E9.5–E11.5. EM refers to the caudal half of the embryo at E9.5 and the aorta-
om three (E9.5), seven (E10.5), and three (E11.5) independent experiments and
(legend on next page)
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active during fertilization, enabling Cre recombination in all cells
of the conceptus (data not shown) (Gallardo et al., 2007). Hence,
using two different Cre lines, we verified that the absence of YFP
signal in Lyve1-Cre;YFP E9.0 primitive erythroid cells was not ex-
plained by silencing of the Rosa26 locus. Later in development,
however, Lyve1-Cre tracing of primitive erythroid cells could not
be tracked because reporter expression from the Rosa26 locus
was silenced as the primitive erythroid cells matured, irrespec-
tive of the Cre line used (data not shown).
Lack of Lyve1-Cre labeling in primitive erythroid cells was
confirmed by analyzing E9.5 Lyve1-Cre;RosamT/mG concepti.
Although many CD43+ hematopoietic cells in YS had switched
from tdTomato to GFP expression, CD71+Ter119+ primitive
erythroid cells retained tdTomato expression (Figure S2A), doc-
umenting absent Lyve1-Cre marking, despite intact activity of
the Rosa26 locus. These data confirm that the primitive erythroid
lineage does not originate from LYVE1-expressing hemogenic
endothelium.
In contrast to the unlabeled primitive erythroid cells, 69.7% ±
14.8% SD of CD41midcKit+ HSPCs in E9.5 Lyve1-Cre;YFP YS
was marked by YFP (Figures 3D and 3G). These data imply
that Lyve1-Cremarks the stage when the precursors generating
YS definitive hemogenic endothelium and HSPCs have sepa-
rated from the primitive erythroid lineage.
Lyve1-Cre Labels a Subset of Fetal and Adult HSCs
To investigate whether Lyve1-Cre marking is restricted to EMPs
or includes HSCs, we assessed the contribution of lineage-
traced cells to fetal and adult HSCs. At E13.5, when the FL
HSC compartment has become established and is rapidly ex-
panding, 38.9% ± 11.6% SD of the LSK CD150+ HSCs were
YFP marked (Figures 3E and 3G). In the adult, comparable frac-
tions of YFP labeling were found among LSK CD150+ HSCs
(37.4% ± 11.1% SD) and Mac1+Gr1+ myeloid cells (38.2% ±
6.0% SD) in the bone marrow (BM) and CD4+CD8+ T lympho-
cytes (39.4% ± 3.5% SD) in the thymus (Figures 3F and 3G).
The uniform degree of post-natal Lyve1-Cremarking in all major
lineages is in stark contrast to the absent or low expression ofFigure 3. Lyve1-Cre Targets Yolk-Sac-Definitive Hematopoiesis
(A) Schematic of mouse model for tracing Lyve1-Cre-marked cells using the R26
(B) Representative FACS plots of E8.5 conceptus show Lyve1-Cre;YFP labeling in
(C) Representative FACS plots of E9.0 YS demonstrate labeling of Ter119+ pRBC
(D) Representative FACS plots of E9.5 YS demonstrate labeling of YS CD41midc
(E and F) Representative FACS plots display similar YFP marking in the LinSca
(G) Quantification shows a contrast of YFP marking between pRBCs (n = 4, two in
Lyve1-Cre marking in E13.5 FL LinSca1+cKit+CD150+ HSCs (n = 15, 4 indepen
myeloid cells (n = 8, two independent experiments), and thymus CD4+CD8+ T
populations yielded statistical difference. Data are represented as mean ± SD.
(H) Representative FACS plots of E9.5 Lyve1-Cre;YFP Ncx1/ concepti show p
circulation is absent.
(I) Quantification of YFP+ fraction in HSPCs of E9.5 Ncx1/ concepti with impair
independent experiments are represented as mean ± SD; **p value of the differe
(J) Representative FACS plots and quantification of HSPCs in hemogenic organs
conditional deletion of Runx1 in LYVE1 lineage cells. The loss in HSPCs is partial
controls from three independent experiments are represented as mean ± SD. p
(K) Quantification ofmyelo-erythroid colonies per embryo equivalent (ee) from each
experiments are represented as mean ± SD.
(L) Genotyping of Runx1 alleles in representative colonies.
See also Figure S2 and Table S1.
2292 Cell Reports 17, 2286–2298, November 22, 2016LYVE1 protein in HSCs or in cells committed to the different
hematopoietic lineages (Figure S2B). These data establish that
more than one-third of long-term repopulating HSCs derive
from the Lyve1-Cre lineage, and that they were labeled during
embryonic development.
YS Is the Primary Source of Lyve1-Cre Lineage-Derived
HSPCs at Mid-gestation
Although the YS was the only hemogenic organ that showed
extensive Lyve1-Cre labeling of endothelium during HSPC emer-
gence (Figure 2F), the PL (Figures 3H and 3I) and EM (data
not shown) also harbored CD41midcKit+ HSPCs with reporter
expression. To examine how circulating cells contribute to the
HSPC census in each hemogenic organ, YFP fluorescence
was examined in blood cells of heartbeat-deficientNcx1/ con-
cepti. Although the YS maintained the richly labeled HSPC pool
(79% ± 2.8% SD), the absence of circulation in Ncx1/mutants
depleted YFP+ labeled HSPCs from the PL (Figures 3H and 3I).
The CD16/32+ EMP subset in Ncx1/ mutants also showed a
similar redistribution of YFP+ fractions (Figure S2C). These
data suggested that the YS is themain source of Lyve1-Cre-line-
age-traced HSPCs and EMPs at mid-gestation. Due to the
severely defective generation of HSPCs in the Ncx1/ mutant
embryos, labeling of HSPCs generated in this organ could not
be reliably assessed.
To target the hematopoietic cells derived from the LYVE1 line-
age, Lyve1-Crewas used to delete the Runt-related transcription
factor 1 (Runx1) gene, which is required for the generation of
EMPs and HSCs. Comparison of Lyve1-Cre;Runx1fl/ concepti
to control tissues at E9.5 showed near depletion of CD41midckit+
HSPCs in the conditional knockout YS. Both the PL and EM
showed a partial reduction in their HSPC populations, likely re-
flecting the lack of migration of Lyve1-Cre-depleted HSPCs
from the YS. The HSPC populations observed in the PL and
EM likely represent the HSPCs generated in situ, which were un-
affected by Lyve1-Cre mediated Runx1 deletion (Figure 3J). A
parallel defect in myelo-erythroid colony formation was evident
in Lyve1-Cre;Runx1fl/ YS (Figure 3K). As expected from the-stop-YFP reporter.
Tie2+CD31+ angioblasts, but not in Ter119+ primitive erythroid cells (pRBCs).
by Tie2-Cre, but not by Lyve1-Cre.
Kit+Ter119 HSPCs and CD16/32+ EMPs by Lyve1-Cre.
1+cKit+CD150+ HSC of E13.5 FL (E) and 8-month-old adult BM (F).
dependent experiments) and YS HSPCs (n = 15, 7 independent experiments).
dent experiments) is similar to 8-month-old adult BM HSCs, BM Mac1+Gr1+
lymphocytes (n = 7, two experiments). No comparison of marking between
reservation of YFP+ HSPCs in the YS but near depletion in the PL when blood
ed circulation. Data from n = 16 for Ncx1CTR and n = 5 for Ncx1/ from three
nce in YFP+ fractions at% 0.01.
of E9.5 Lyve1-Cre;Runx1fl/- tissues show depletion of HSPCs from the YS upon
in the PL and insignificant in the EM. Data from n = 4 for mutants and n = 9 for
values are shown as ns if > 0.05; *P% 0.05; **P% 0.01.
organ. Data from n= 4 formutants and n = 3 for controls from two independent
known function of Runx1 in hemogenic endothelium (Chen et al.,
2009), genotyping of YS colonies confirmed that only rare cells
that had escaped Lyve1-Cre-mediated Runx1 deletion formed
colonies (Figure 3L). These genetic labeling and gene ablation
data verified that YS HSPCs are efficiently targeted by Lyve1-
Cre, whereas the PL and EM harbor native HSPCs that do not
originate from the LYVE1 lineage.
Lyve1-Cre Lineage Tracing Identifies a Temporal Switch
in the Precursors Responsible for FL Erythropoiesis
To investigate the contribution of Lyve1-Cre lineage cells to FL
hematopoiesis, we assessed the fraction of lineage-traced cells
in different hematopoietic populations frommid to late gestation.
Lyve1-Cre marking in the FL LincKit+CD34+Sca1+ HSC
compartment peaked at E11.5 (61.3% ± 17.8% SD), when the
FL seeding by HSCs begins, and leveled to 36.4% ± 11.7% SD
at E13.5 and 41.4% ± 10.4% SD at E16.5 (Figures 4A and 4D).
Of note, CD150, the Slam family marker associated with long-
term reconstituting HSCs in mice (Kiel et al., 2005) was not
used in E11.5 FL because it is not reliably expressed inHSCs dur-
ing early FL colonization (McKinney-Freeman et al., 2009). How-
ever, incorporating CD150 expression to further characterize
HSCs at E13.5 did not change their fraction of Lyve1-Cremarking
(data not shown). These data suggest that LYVE1-lineage cells
are major contributors to initially colonize the FL HSC compart-
ment, whereas by E13.5, non-lineage-traced HSCs co-seed the
FL. The uniform degree of HSC marking from E13.5 to adult im-
plies that the respective contributions of Lyve1-Cre labeled and
non-labeled HSCs to the HSC pool remains stable after the FL
HSC compartment has been established by E13.5.
In addition to serving as a site for HSC expansion, the FL sup-
ports definitive erythropoiesis through most of the fetal life.
Whereas the primitive erythroid cells differentiate in the YS and
undergo maturation in circulation, the progenitors for definitive
erythroid cells must transit through the FL to differentiate and
enucleate (McGrath et al., 2011). It has been proposed that the
precursors that first colonize the FL and initiate definitive eryth-
ropoiesis derive from the YS, but their origin and the duration
of their contribution have not been experimentally proven.
FACS analysis of Lyve1-Cre;YFP FL at E11.5 revealed that
it contained CD71+Ter119 pro-erythroblasts (ProE) and ckit+
CD34 hematopoietic progenitor cells (HPCs) with extensive
YFP marking (76.7% ± 4.7% SD and 79.3% ± 3.0% SD, respec-
tively) (Figures 4A and 4D), which was comparable to the level
measured in E9.5 YS CD41midcKit+ HSPCs (Figures 3D and
3G). This suggests that the YS supplies the precursors that first
colonize the FL to initiate definitive erythropoiesis. By E13.5,
63.2% ± 8.7% SD of the ProE and 51.0% ± 5.5% SD of FL
HPCs derived from the LYVE1 lineage (Figures 4B and 4D).
These compartments displayed significantly higher marking
than the LinSca1+cKit+CD34+ HSC subset (36.4% ± 11.7%
SD), implicating that the progenitors responsible for FL-definitive
erythropoiesis derive from a different source than most HSCs at
this stage. By E16.5, the ProE- and HSC-enriched populations
exhibited similar degrees of Lyve1-Cre marking (41.2% ± 8.1%
SD and 41.4% ± 10.3% SD, respectively), suggesting that by
late gestation, HSCs become responsible for FL erythropoiesis
(Figures 4C and 4D).Lyve1-Cre-Mediated Deletion of Scl/Tal1 Targets Early
FL Definitive Erythropoiesis but Spares the Primitive
Erythroid Lineage
To confirm that the Lyve1-Cre strain can be used to manipulate
early definitive erythropoiesis without affecting primitive erythro-
poiesis, we created a Lyve1-Cre-mediated conditional knockout
of the transcription factor SCL. Although SCL is essential for the
specification of hemogenic endothelium (Porcher et al., 1996;
Van Handel et al., 2012), it is dispensable for HSC maintenance
(Mikkola et al., 2003a) because of redundancy with LYL1 (Sour-
oullas et al., 2009). Because SCL is required for the terminal dif-
ferentiation of all erythroid cells, inactivation of Scl by Tie2-Cre
results in defects in both primitive and definitive erythropoiesis
(Schlaeger et al., 2005). As previously reported, May-Grunwald
Giemsa stain of E12.5 peripheral blood from Tie2-Cre;Sclfl/- mu-
tants displayed abnormal primitive erythroid cells that were
mitotic, binucleated, or had a larger nucleus-to-cytoplasm ratio
than control littermates, implying defective maturation (Fig-
ure 5A). Furthermore, 2-hr 5-Bromo-2’-deoxyuridine (BrDU)
pulse analysis showed a high fraction of mutant erythroid cells
undergoing DNA replication (Figure 5B). In contrast, when Scl
was excised in Lyve1-Cre-expressing cells, the primitive
erythroid cells did not show abnormal morphology or prolifera-
tion, indicating that they had been spared from Scl inactivation
(Figures 5A and 5B).
Both Tie2-Cre;Sclfl/ and Lyve1-Cre;Sclfl/ E12.5 fetal livers
showed an increase in the CD71+Ter119 ProE fraction (Figures
5C and 5E), consistent with delayed maturation reported in
Scl-deficient definitive erythroid cells (Mikkola et al., 2003a;
Schlaeger et al., 2005). This defect was ameliorated by E13.5
(Figures 5D and 5E), likely due to replenishment of the FL ProE
pool by a new source of unaffected precursors. These data
verify that Lyve1-Cre deletes Scl specifically from the transient-
definitive, but not primitive erythroid cells, enabling studies that
address the impact of the different erythroid waves on embry-
onic development.
DISCUSSION
The challenge of tracking the origin and contribution of the
different waves of developmental hematopoiesis in vivo has
limited the understanding of their unique roles in the embryo
and adult. We report that LYVE1 expression and lineage tracing
can be used to specifically examine the definitive hematopoiesis
originating from the YS and/or vitelline vessels without targeting
the primitive erythroid lineage or the majority of the HSC
compartment generated elsewhere in the conceptus.
LYVE1 protein expression and Lyve1-Cre fate mapping distin-
guished endothelial cells from the YS and vitelline vessels from
those from other hemogenic organs at the developmental win-
dow when HSPCs emerge. Although LYVE1+ EMPs and HSPCs
could be detected in all hemogenic organs in concepti with
normal circulation, analysis of heartbeat-deficient Ncx1/ con-
cepti implied that the YS is themain source of LYVE1+ HSPC and
EMPs. These data propose that some, if not all, HSCs of Lyve1-
Cre lineage, which constitute more than one-third of the fetal and
the adult HSC pools, originate from the YS and/or vitelline ves-
sels. However, because LYVE1 protein expression appears inCell Reports 17, 2286–2298, November 22, 2016 2293
Figure 4. Progenitors of Lyve1-Cre Lineage Initiate Fetal Liver Hematopoiesis
(A) Representative FACS plots of Lyve1-Cremarking in hematopoietic subpopulations in one representative E11.5 FL: Ter119 CD71+ proerythroblasts (ProEs),
Ter119cKit+ HPCs, and Ter119CD34+cKit+Sca1+ HSPCs.
(B) Representative FACS plots of FL subsets at E13.5.
(C) Representative FACS plots of FL subsets at E16.5.
(D) Comparative analysis of E11.5, E13.5, and E16.5 FL illustrates a shift in hematopoietic populations derived from the Lyve1-Cre lineage. Data from n = 9, three
independent experiments for E11.5, n = 18, three independent experiments for E13.5, and n = 13, two independent experiments for E16.5, are represented as
mean ± SD. p values are shown as ns if > 0.05; *P% 0.05; **P% 0.01; ***P% 0.001; ****P% 0.0001.
See also Table S1.PL vasculature at late gestation and a low level of Lyve1-Cre
marking is noted in PL and EM endothelium at mid-gestation,
our data do not exclude the possibility that other hemogenic2294 Cell Reports 17, 2286–2298, November 22, 2016organs may also contribute to the LYVE1-lineage-traced HSC
pool. The Ncx1/ model cannot be used to assess adult-repo-
pulating HSC activity of Lyve1-Cre-marked cells because these
Figure 5. Lyve1-Cre Targets Early Fetal Liver
Definitive Hematopoiesis
(A) May-Grunwald Giemsa stain of E12.5 peripheral
blood (PB) shows primitive erythroid defects in
Tie2-Cre;Sclfl/ blood cells (arrows), but not in
Lyve1-Cre;Sclfl/ blood. Representative images
from three independent experiments are shown.
(B) Representative FACS plots of BrDU staining
of E12.5 PB illustrate excessive proliferative ac-
tivity in Tie2-Cre;Sclfl/ primitive erythroid cells,
but not in Lyve1-Cre;Sclfl/ cells. Bar graphs
from n = 22 controls and n = 4 knockouts from
three independent Tie2-Cre;Sclfl/ experiments
and n = 6 controls and n = 3 knockouts from two
independent Lyve1-Cre;Sclfl/ experiments are
shown as mean ± SD.
(C) E12.5 FLs from both Tie2-Cre;Sclfl/ (upper
panel) and Lyve1-Cre;Sclfl/ (lower panel) embryos
exhibit accumulation of proerythroblasts (ProEs).
(D) At E13.5, the defect in ProE fraction in Lyve1-
Cre;Sclfl/ FL has corrected.
(E) Quantification of ProE fractions in E12.5 and
E13.5 FL. Data from n = 2 (E12.5 Tie2-Cre;Sclfl/)
and n = 6 (control), n = 3 (E12.5 Lyve1-Cre;Sclfl/)
and n = 7 (control), and n = 4 (E13.5 Lyve1-Cre;
Sclfl/) and n = 14 (control) from two independent
experiments for each genotype and age are shown
as mean ± SD.
See also Table S1.embryos die by E10.0—before transplantable HSCs can be har-
vested—and because heartbeat is critical for proper HSC devel-
opment (North et al., 2009). Hence, the question of whether all or
most of the 35%–40% Lyve1-Cre-marked fetal and adult HSPCs
arise from the YS and/or vitelline vessels requires further studies
using different experimental systems. Nevertheless, because the
YS generates predominantly Lyve1-Cre-marked HSPCs, while
the PL and the EMproducemostly unmarked ones, our data pro-
pose that HSCs from multiple anatomical sites contribute to
adult hematopoiesis. How these different lineages of HSCs
contribute to the various hematopoietic subsets in the adult
can now be approached experimentally in vivo using the
Lyve1-Cremodel. This is important because HSCs are heteroge-Cell Reportneous and can show cell intrinsic biases to
different hematopoietic lineages in an
age-dependent manner (Beerman et al.,
2010; Benz et al., 2012; Pang et al.,
2011; Sieburg et al., 2006; Yamamoto
et al., 2013).
Our data document that the LYVE1+
endothelium in the YS does not give rise
to primitive erythroid cells. The absence
of LYVE1 protein expression and marking
in the primitive erythroid cell contrasts
with the abundant protein expression
and marking in YS definitive HSPC. These
data imply that these two hematopoietic
lineages have separated from a common
mesodermal precursor before Lyve1-Cre
becomes active. The YS thus gives riseto at least two lineages of erythroid cells that originate from
distinct precursors. The Lyve1-Cre lineage trace may thus pro-
vide clarity to studies that challenged the ‘‘lineage switchmodel’’
by reporting that the types of globins expressed in primitive or
definitive erythroid lineages are not mutually exclusive because
the cells undergo ‘‘maturational globin switch’’ during erythroid
differentiation (Kingsley et al., 2006; McGrath et al., 2011; Palis,
2008; Qiu et al., 2008).
LYVE1 expression and lineage tracing offer a powerful tool
to separate primitive erythroid lineage from early fetal definitive
erythropoiesis. The defects in both primitive and definitive
erythroid cell differentiation caused by the conditional deletion
of Scl by Tie2-Cre (Schlaeger et al., 2005) were uncoupled usings 17, 2286–2298, November 22, 2016 2295
Lyve1-Cre, which disrupted only the early FL definitive erythro-
poiesis. Selective inactivation of key hematopoietic regulators
in Lyve1-Cre progenies makes it possible to study the require-
ment of such factors in early FL erythropoiesis without the
confounding effects of early embryonic lethality, as in Scl null
embryos (Porcher et al., 1996; Shivdasani et al., 1995), or prim-
itive erythroid defects, as in Tie2-Cre;Sclfl/ concepti.
The Lyve1-Cre model also provides in vivo evidence that the
earliest progenitors seeding and initiating FL erythropoiesis are
products of a distinct lineage that likely emerges from the YS.
However, the deletion of Scl in LYVE1-lineage cells causes
only a temporary effect on FL erythropoiesis, possibly because
progenitors from other sources that were spared from Lyve1-
Cre deletion also converge to the FL and replenish the initially
attenuated erythroid compartment. Future studies will inform
whether the erythroid progenitors or HSCs belonging to the
LYVE1 lineage exhibit different properties than those arising
from non-LYVE1-lineage precursors.
LYVE1 is expressed abundantly in lymphatic vessels and
lymph node sinus endothelial cells, but its expression has also
been described in other cell types, such as liver blood sinusoids
and tissuemacrophages (MoutaCarreira et al., 2001; Phamet al.,
2010; Schledzewski et al., 2006). In the YS, LYVE1 expression is
not related to lymphatic identity because the YS does not contain
lymphatic vasculature (Banerji et al., 1999; Gordon et al., 2008). It
is unknown how the YS- and vitelline-vessel-restricted expres-
sion pattern of LYVE1 among hemogenic vessels is established,
and whether this is intrinsically regulated or if it involves signals
from the microenvironment. It will be interesting to determine
whether LYVE1 expression is also enriched in YS and vitelline
vessels and HSPCs during human development, and how the
expression pattern is preserved during ESC differentiation.
The functional significance of LYVE1 expression in YS endo-
thelial or hematopoietic cells is unknown. Although it was sug-
gested to serve in cell adhesion/transmigration and as a scav-
enger for hyaluronan turnover, mouse knockout studies in
either 129/C57BL/6 or C57BL/6 background were unable to
demonstrate a critical function for LYVE1 in these processes or
in embryonic development in general (Gale et al., 2007). The
Cre cassette was inserted into the 30UTR of the endogenous
Lyve1 locus, avoiding disruption in the LYVE1 protein. Hence,
our model cannot be used to answer whether loss of LYVE1
causes subtle effects in hematopoiesis that would be observed
upon more detailed examination or backcrossing to other ge-
netic backgrounds. However, because of the hematopoietic
wave- and tissue-restricted expression of LYVE1, the Lyve1-
Cre model can be exploited to uncover new functions for the
different blood progenitor lineages and HSC sources during
developmental and adult hematopoiesis.
EXPERIMENTAL PROCEDURES
Mouse Models
Lyve1-eGFP-hCre knockin mice (C57BL/6) (Pham et al., 2010) were crossed
with two reporter lines: (1) R26-YFP carrying a floxed transcriptional stop up-
stream of the YFP in Rosa26 locus (Srinivas et al., 2001), and (2) double-fluo-
rescent reporter (RosamT/mG), where cells express Tomato constitutively but
switch to GFP upon excision (Muzumdar et al., 2007). Whereas YFP or GFP
fluorescence rendered from crossing with the reporter lines could clearly high-2296 Cell Reports 17, 2286–2298, November 22, 2016light the Cre-excised cells, eGFP from Lyve1-eGFP-hCre alone could not be
discerned by fluorescence microscopy, as previously reported (Pham et al.,
2010). FACS analysis confirmed the low eGFP signal from Lyve1-eGFP-
hCre, which did not overlap with the intense YFP or GFP signal. Hence, for
simplicity, the Lyve1-eGFP-hCre is referred as Lyve1-Cre. To label the entire
hemato-vascular compartment, Tie-2/Tek-Cre mice (Kisanuki et al., 2001)
were bred with the R26-YFP line. To label all cells of the conceptus, the
germ-cell-specific Vasa-Cre was crossed with the R26-YFP line. Lyve1-
Cre;YFP mice were further crossed with Ncx1+/ mice (Koushik et al., 2001)
to generate Ncx1/ mutants that underwent Lyve1-Cre labeling and lacked
circulation. Although some contaminating embryonic red blood cells (RBCs)
could occasionally be found in the embryo proper of Ncx1/ concepti, only
embryos with less than 5% RBC contamination were used in the analysis.
Lyve1-Cre was also bred with Runx1fl/ (Growney et al., 2005; Wang et al.,
1996) and Sclfl/- (Mikkola et al., 2003a; Shivdasani et al., 1995). Embryos
were not separated based on sex, and both female and male embryos were
studied. Mice were maintained according to protocols of Animal Research
Committee at the University of California, Los Angeles, and the University of
California, Irvine, who approved these studies.
See the Supplemental Experimental Procedures for preparation of tissue
sections, immunostaining, flow cytometry, clonogenic progenitor assay, cyto-
spin, cell proliferation assay, and statistical analysis.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
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